Archive \ Volume.15 2024 Issue 2

Clinical Relevance of Therapeutic Drug Monitoring of Busulfan-Based Regimens in Adult Hematopoietic Stem Cell Transplant Patients

, , , , ,
  1. Department of Pharmacy Practice, College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.
  2. Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia.
  3. College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia 4Department of Internal Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
  4. Department of Hematology, King Saud Bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
  5. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Abstract

Hematopoietic stem cell transplant (HSCT), also known as bone marrow transplantation, is a therapeutic procedure that revolutionizes the treatment landscape for various debilitating conditions, including hematological malignancies and genetic disorders. Busulfan, an alkylating agent, plays a pivotal role in this regimen by eradicating malignant tumor cells and replacing unhealthy cells with healthy ones. In recent years, therapeutic drug monitoring (TDM) has emerged as a valuable tool for optimizing the dosing strategies of busulfan-based regimens in adult HSCT patients. This narrative review aims to comprehensively assess the clinical relevance and significance of TDM explicitly about busulfan-based regimens in adult HSCT patients. This review explores and analyzes existing literature, focusing on the efficacy, safety, and practical implications of utilizing TDM to optimize busulfan dosing strategies in this patient population. A review of English written literature on PubMed, Google Scholar, and Cochrane Library was performed on the terms "busulfan and pharmacokinetics" and "transplant and conditioning". The evidence is presented first on factors influencing Busulfan clearance and volume distribution. Then, the need to implement TDM of busulfan-based regimens in adult patients is discussed. A large-scale trial is required to demonstrate the benefit of anticipating and avoiding Adverse Drug Reactions and sufficient dosage to reach desired objectives. Future research on TDM of busulfan-based regimens in adult HSCT patients must address several critical issues.


Downloads: 17
Views: 37

How to cite:
Vancouver
Alanazi RJ, Alrajhi AM, Rajah A, Alsaeed N, Alzahrani M, AlSultan A. Clinical Relevance of Therapeutic Drug Monitoring of Busulfan-Based Regimens in Adult Hematopoietic Stem Cell Transplant Patients. Arch Pharm Pract. 2024;15(2):12-9. https://doi.org/10.51847/0gP4fKV7Ez
APA
Alanazi, R. J., Alrajhi, A. M., Rajah, A., Alsaeed, N., Alzahrani, M., & AlSultan, A. (2024). Clinical Relevance of Therapeutic Drug Monitoring of Busulfan-Based Regimens in Adult Hematopoietic Stem Cell Transplant Patients. Archives of Pharmacy Practice, 15(2), 12-19. https://doi.org/10.51847/0gP4fKV7Ez

Download Citation
References
  1. Khaddour K, Hana CK, Mewawalla P. Hematopoietic stem cell transplantation. [Updated 2023 May 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536951/
  2. Maedler-Kron C, Marcus VA, Michel RP. Hematopoietic stem cell transplantation. Pathology of Transplantation: A Practical Diagnostic Approach. 2016:401-49.
  3. Barriga F, Ramírez P, Wietstruck A, Rojas N. Hematopoietic stem cell transplantation: Clinical use and perspectives. Biol Res. 2012;45(3):307-16.
  4. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: One size does not fit all. Blood. 2014;124(3):344-53. 
  5. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10.
  6. Simeoli R, Dorlo TPC, Hanff LM, Huitema ADR, Dreesen E. Editorial: therapeutic drug monitoring (TDM): A useful tool for pediatric pharmacology applied to routine clinical practice. Front Pharmacol. 2022;13:931843.
  7. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52 Suppl 1(Suppl 1):5S-10S.
  8. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Ther Drug Monit. 2019;41(3):261-307. 
  9. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24(3):330-50. 
  10. Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, et al. Therapeutic drug monitoring of posaconazole: An update. Curr Fungal Infect Rep. 2016;10(2):51-61.
  11. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20(5):543-9. 
  12. van der Stoep MYEC, Oostenbrink LVE, Bredius RGM, Moes DJAR, Guchelaar HJ, Zwaveling J, et al. Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation; Where do we stand? Front Pharmacol. 2022;13:826004. 
  13. Menz BD, Stocker SL, Verougstraete N, Kocic D, Galettis P, Stove CP, et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol. 2021;87(2):227-36.
  14. Fang Z, Zhang H, Guo J, Guo J. Overview of therapeutic drug monitoring and clinical practice. Talanta. 2024;266(Pt 1):124996.
  15. Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol. 2013;69(1):25-32.
  16. Bates DW. Improving the use of therapeutic drug monitoring. Ther Drug Monit. 1998;20(5):550-5.
  17. Salman B, Al-Khabori M. Applications and challenges in therapeutic drug monitoring of cancer treatment: A review. J Oncol Pharm Pract. 2021;27(3):693-701.
  18. Schuler U, Schroer S, Kühnle A, Blanz J, Mewes K, Kumbier I, et al. Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted? Bone Marrow Transplant. 1994;14(5):759-65.
  19. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous Busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous Busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(4):472-9.
  20. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100(6):1977-83.
  21. Kitko CL, Gatwood K, Connelly J. Preparing the patient for HSCT: Conditioning regimens and their scientific rationale. Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. 2018:139-74.
  22. Jethava Y, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transplant. 2017;52(11):1504-11.
  23. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523-36.
  24. Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: Retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5(4):e161-9.
  25. Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, et al. Intravenous busulfan-based Myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22(8):1424-30.
  26. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol. 2009;21 Suppl 1(Suppl 1):S3-5. 
  27. Sharma A, Brooke RJ, Bhatt NS, Li Y, Allewelt HB, Bies JJ, et al. Reduced intensity vs myeloablative conditioning regimen for pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia. Biol Blood Marrow Transplant. 2019;25(3):S14-S5.
  28. Keusch F, Rao R, Chang L, Lepkowski J, Reddy P, Choi SW. Participation in clinical research: Perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(10):1604-11.
  29. Frangoul H, Najjar J, Simmons J, Domm J. Long-term follow-up and management guidelines in pediatric patients after allogenic hematopoietic stem cell transplantation. Semin Hematol. 2012;49(1):94-103.
  30. Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant. 2009;44(3):145-56.
  31. Salman B, Al-Za'abi M, Al-Huneini M, Dennison D, Al-Rawas A, Al-Kindi S, et al. Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients. Hematol Oncol Stem Cell Ther. 2017;10(2):70-8.
  32. Gürlek Gökçebay D, Azik F, Ozbek N, Isik P, Avci Z, Tavil B, et al. Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. Pediatr Transplant. 2015;19(3):307-15.
  33. Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajinovic M, Ansari M. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr Drug Metab. 2014;15(3):251-64.
  34. Seydoux C, Battegay R, Halter J, Heim D, Rentsch KM, Passweg JR, et al. Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2022;57(6):903-10.
  35. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS-L, et al. Acute safety and pharmacokinetics of intravenous Busulfan when used with oral Busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant. 2000;6(5):548-54.
  36. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, et al. Pharmacokinetics of once-daily IV Busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007;13(1):56-64.
  37. Chen RL, Fang LH, Yang XY, El Amrani M, Uijtendaal EV, Chen YF, et al. Therapeutic drug monitoring of Busulfan in patients undergoing hematopoietic cell transplantation: A pilot single-center study in Taiwan. Pharmaceuticals. 2021;14(7):613.
  38. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936-49. 
  39. Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: Towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331-45. 
  40. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol. 2002;53(4):386-9. 
  41. Abbasi N, Vadnais B, Knutson JA, Blough DK, Kelly EJ, O'Donnell PV, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011;51(10):1429-38.
  42. Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):231-41. 
  43. Lawson R, Staatz CE, Fraser CJ, Hennig S. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet. 2021;60(1):17-51. 
  44. Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, et al. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: A comprehensive review. Expert Opin Drug Metab Toxicol. 2017;13(9):901-23.
  45. Choong E, Uppugunduri CRS, Marino D, Kuntzinger M, Doffey-Lazeyras F, Lo Piccolo R, et al. Therapeutic drug monitoring of busulfan for the management of pediatric patients: Cross-validation of methods and long-term performance. Ther Drug Monit. 2018;40(1):84-92.
  46. Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant. 2015;21(8):1471-8.
  47. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5(8):957-69.
  48. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: Dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2(1):75-91. 
  49. Shao DF, Li JH, Hu T, Zhang ZX, Zhang L, Li JJ, et al. Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring. Bone Marrow Transplant. 2022;57(3):473-8. 
  50. Spinewine A, Byrne S, Dalleur O. The role of pharmacists in optimising drug therapy. Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach: Springer; 2023. p. 105-17.
  51. Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, Cooper-Dehoff RM, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 2014;34(10):1102-12. 

 


Related articles:
Most viewed articles:
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.